Latest news with #SarahCannonResearchInstitute
Yahoo
03-07-2025
- Business
- Yahoo
Veeva Systems and Sarah Cannon Partner to Accelerate Cancer Clinical Trials
Veeva Systems Inc. (NYSE:VEEV) is one of the top 10 healthcare AI stocks to buy according to hedge funds. A team of IT experts monitoring a network of computers managing the medical content and communications. Veeva Systems Inc. (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) announced a strategic collaboration aimed at advancing oncology clinical trials across more than 200 research sites. Through this partnership, SCRI will implement Veeva's Clinical Platform to unify its contract research and site operations on a single, cloud-based infrastructure. The move is expected to streamline workflows, reduce startup delays, and enhance coordination between clinical teams, ultimately accelerating the delivery of novel cancer therapies to patients. According to Yazhene Krishnaraj, Chief Information and Digital Officer at SCRI, the platform will empower the institute's teams to operate with greater precision and speed. Jim Reilly, President of Veeva Development Cloud, noted the collaboration is a 'first-of-its-kind' and will set a new benchmark for clinical trial execution and site engagement. The initiative reflects both organizations' commitment to improving trial efficiency at scale. The collaboration not only enhances SCRI's operational capacity but also reinforces Veeva's growing role in transforming clinical research through intelligent, AI-powered solutions. Veeva's Clinical Platform includes tools such as electronic data capture, clinical trial management, regulatory document tracking, and remote site monitoring—all integrated into one system. It also incorporates artificial intelligence and machine learning to identify trial risks, predict site performance, and flag data anomalies before they disrupt studies. These AI capabilities solidify Veeva's position as a key player in healthcare technology, helping research organizations make faster, data-driven decisions. While we acknowledge the potential of VEEV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VEEV and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None.
Yahoo
10-06-2025
- Business
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Looking for Strong Returns? These 5 US Growth Stocks Could Be Perfect for Your Portfolio
Have you ever wondered how to grow your investment portfolio to comfortably fund your retirement? The answer is to park your money in well-run, high-quality companies that can demonstrate consistent growth. Such promising growth stocks should see their share prices rise steadily over time, providing you with valuable capital appreciation and increasing the value of your nest egg. Here are five growth stocks with solid market positions that are demonstrating healthy growth that you can add to your buy watchlist. Veeva runs a software-as-a-service cloud platform for the life sciences industry. The company serves over 1,000 customers, ranging from large pharmaceutical companies to emerging biotechnology firms. For the first quarter of fiscal 2026 (1Q FY2026) ending 30 April 2025, Veeva saw revenue rise 16.7% year on year to US$759 million. Operating profit surged 50.6% year on year to US$233.7 million while net profit climbed 41.2% year on year to US$228.2 million. The business also churned out a positive free cash flow of US$871.2 million, 15% higher than a year ago. For the quarter, Veeva achieved its revenue run rate goal of US$3 billion, showcasing growth across its Commercial and R&D Solutions. Management believes the company is progressing well towards its 2030 goals to double revenue. Last week, Veeva collaborated with Sarah Cannon Research Institute to drive speed and efficiency in oncology clinical trials, with the latter adopting Veeva's platform to ensure seamless data flow across its clinical teams and research sites. MarketAxess provides a leading electronic platform that allows more than 2,000 firms to efficiently trade fixed income securities. The company's platform provides a diversified pool of liquidity and generates cost savings for institutional investors and broker-dealers. MarketAxess reported steady growth over the years, with revenue rising from US$718.3 million in 2022 to US$817.1 million by 2024. Net profit went from US$250.2 million to US$274.2 million over the same period. The business also generated healthy free cash flow over these three years. For the first quarter of 2025 (1Q 2025), total revenue dipped by 1% year on year to US$208.6 million while operating profit slipped 4% year on year to US$88.4 million. Net profit plunged 79% year on year to US$15.1 million because of a significantly higher tax expense. Notwithstanding this, MarketAxess continued to generate free cash flow of US$12.7 million for the quarter, reversing the prior year's negative free cash flow of US$20.1 million. Operationally, the company reported record average daily volume (ADV), up 31% year on year. It also achieved record emerging market and Eurobonds ADV with an 11% year-on-year increase. The company paid out a quarterly dividend of US$0.76, up from the previous year's US$0.74. Domino's Pizza is one of the largest pizza chains in the world, with more than 21,300 stores located in over 90 countries. The company reported an encouraging set of results for the first quarter of 2025 ending 23 March 2025. Revenue inched up 2.5% year on year to US$1.11 billion, but operating profit dipped 0.2% year on year to US$210.1 million. Net profit climbed almost 19% year on year to US$149.7 million. Free cash flow for the quarter shot up 59.1% year on year to US$164.3 million. A quarterly dividend of US$1.74 was declared and paid, higher than the US$1.51 per share paid out in the prior year. Domino's Pizza recorded negative same-store sales growth of 0.5% for its US stores but logged a +3.7% same-store sales increase for its international stores. Back in April, Domino's Pizza partnered with DoorDash (NASDAQ: DASH) to help fulfil orders on the latter's platform while tapping into DoorDash's customer base. The US launch commenced in May 2025 and will be expanded to Canada later this year. Asana provides a work management platform that helps more than 170,000 customers align their corporate teams to achieve organisational goals. The company uses artificial intelligence (AI) to improve its customers' workflows and processes, which helps to improve efficiency and deliver results. For 1Q FY2026, Asana reported an 8.6% year-on-year increase in revenue to US$187.3 million. Gross profit improved by 8.7% year on year to US$168 million. The business also churned out a positive free cash flow of US$4 million for the quarter, a turnaround from the negative free cash flow of US$4.3 million in the previous corresponding quarter. Customers are also spending more on Asana's platform, with those forking out US$100,000 or more (on an annualised basis) increasing by 20% year on year to 728. Last month, Asana signed its largest subscription agreement in history with a US$100 million-plus renewal over three years. The company also launched Smart Workflow Gallery, a suite of AI-powered workflows designed to help organisations utilise AI to generate greater employee productivity. PayPal is a payment processing company that helps to move money securely and efficiently and to make shopping simple, secure, and personalised. For 1Q 2025, PayPal saw revenue inch up 1.2% year on year to US$7.8 billion. Operating profit grew 31% year on year to US$1.5 billion while net profit leapt 45% year on year to US$1.3 billion. The business generated a positive free cash flow of US$964 million for the quarter. Operating metrics continued to improve, with total payment volume edging up 3% year on year to US$417.2 billion. PayPal's number of active accounts also increased 2% year on year to 436 million. Venmo, one of the products under PayPal's umbrella, recently introduced enhanced rewards in-store and more benefits to encourage more customers to use its service. These rewards will apply to the Venmo Debit Card and Venmo Checkout. Big Tech is spending hundreds of billions on AI, and the ripple effects are just beginning. Our new investor guide shows how AI is changing the way companies generate revenue, structure their business models, and gain an edge. Even if you already know the major players, this report reveals something far MORE important: The why and how behind their moves, and what it means for your portfolio. Download your free report now. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Royston Yang does not own shares in any of the companies mentioned. The post Looking for Strong Returns? These 5 US Growth Stocks Could Be Perfect for Your Portfolio appeared first on The Smart Investor.
Associated Press
04-06-2025
- Business
- Associated Press
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites. 'We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit,' said SCRI chief information and digital officer Yazhene Krishnaraj. 'This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed.' Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites. 'We're excited to work closely with SCRI to drive innovation in oncology research,' said Jim Reilly, president of Veeva Development Cloud. 'In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials.' About Veeva Clinical Platform Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit to learn more. About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at View original content to download multimedia: SOURCE Veeva Systems
Medscape
01-06-2025
- Business
- Medscape
Which Class of ER Degrader Is Better?
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1 -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.
